Emergent Biosolutions reported $425.5M in Stock for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Stock Change
Acadia Pharmaceuticals ACAD:US $ 6.33M 0.68M
Akebia Therapeutics AKBA:US $ 36.27M 3.15M
ALKERMES ALKS:US $ 155.61M 0.82M
Alnylam Pharmaceuticals ALNY:US $ 88.98M 10.46M
Amarin AMRN:US $ 225.77M 42.05M
Ani Pharmaceuticals ANIP:US $ 92.54M 9.39M
Biomarin Pharmaceutical BMRN:US $ 802.32M 15.96M
Chimerix CMRX:US 4.13M 720K
Emergent Biosolutions EBS:US $ 425.5M 24.8M
Exact Sciences EXAS:US $ 115.17M 2.21M
Exelixis EXEL:US $ 33.02M 4.55M
Heron Therapeutics HRTX:US $ 61.32M 4.85M
JAZZ PHA JAZZ:US $ 861.7M 123.75M
Moderna Inc MRNA:US 1.92B 21M
Myriad Genetics MYGN:US $ 15.4M 0.2M
Nektar Therapeutics NKTR:US $ 16.97M 1.59M
Neurocrine Biosciences NBIX:US $ 29.3M 0.3M
Opko Health OPK:US 83.31M 16.1M
Pacira Pharmaceuticals PCRX:US $ 100.59M 3.07M
Ptc Therapeutics PTCT:US $ 15M 0.28M
Sarepta Therapeutics SRPT:US $ 208.1M 9.1M
Seattle Genetics SGEN:US $ 319.35M 43.61M
United Therapeutics UTHR:US $ 89.9M 1.7M
Vanda Pharmaceuticals VNDA:US 1.5M 206K